BIVI Stock: Price, Forecast, Financials & AI Analysis

Loading...

Loading chart...

High

1.435

Open

1.410

VWAP

1.37

Vol

76.83K

Mkt Cap

10.33M

Low

1.310

Amount

105.38K

EV/EBITDA(TTM)

--

Total Shares

7.54M

EV

-10.05M

EV/OCF(TTM)

--

P/S(TTM)

--

BioVie Inc. is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.

Show More

Events Timeline

(ET)

2026-01-08

08:40:00

BioVie Completes Enrollment of 60 Patients in Phase 2 SUNRISE-PD Trial

2025-08-07 (ET)

2025-08-07

20:47:48

BioVie 6M share Secondary priced at $2.00

2025-07-24 (ET)

2025-07-24

08:19:29

BioVie presents data on Bezisterim at WCAG-2025

2025-07-22 (ET)

2025-07-22

08:08:09

BioVie appoints Amy Chappell, Kameel Farag to board of directors

2025-07-09 (ET)

2025-07-09

08:15:26

BioVie reports results from bezisterim Phase 3 NM101 study

2025-06-26 (ET)

2025-06-26

08:13:42

BioVie announces poster on patient-centric accessibility of SUNRISE-PD trial

2025-05-15 (ET)

2025-05-15

08:10:21

BioVie announces first patient enrollment in Phase 2 ADDRESS-LC trial

2025-05-07 (ET)

2025-05-07

08:15:42

BioVie to present design of Phase 2 SUNRISE-PD trial

News

Yahoo Finance

02-21Yahoo Finance

New Show to Air Tonight on Bloomberg Television

Globenewswire

02-12Globenewswire

Halper Sadeh LLC Investigates BioVie Executives' Fiduciary Duties

Yahoo Finance

01-17Yahoo Finance

New to The Street Broadcasts Show #716 Featuring SDST and Others

PRnewswire

2025-12-24PRnewswire

BioVie Inc. Investigated for Potential Breach of Fiduciary Duties by Executives

NASDAQ.COM

2025-11-21NASDAQ.COM

Biotech Stocks Fluctuate Post-Market: Delcath Gains from Buyback, BioVie and Cassava Recover

Newsfilter

2025-11-19Newsfilter

Participate in Biovie's Exclusive Live Investor Webinar and Q&A on December 9

Valuation Metrics

The current forward P/E ratio for BioVie Inc (BIVI.O) is 0.00, compared to its 5-year average forward P/E of -2.49. For a more detailed relative valuation and DCF analysis to assess BioVie Inc's fair value, Click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

dotted line Image

N/A

5Y Average PE

-2.49

Current PE

0.00

Overvalued PE

0.14

Undervalued PE

-5.13

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

dotted line Image

N/A

5Y Average EV/EBITDA

0.00

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

0.00

Undervalued EV/EBITDA

0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

dotted line Image

N/A

5Y Average PS

0.00

Current PS

0.00

Overvalued PS

0.00

Undervalued PS

0.00

Financials

AI Analysis

Annual

Quarterly

Whales Holding BIVI

Trading Trends

People Also Watch

Frequently Asked Questions

What is BioVie Inc (BIVI) stock price today?

The current price of BIVI is 1.37 USD — it has decreased -1.44

What is BioVie Inc (BIVI)'s business?

BioVie Inc. is a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease. In neurodegenerative disease, the Company's drug candidate bezisterim inhibits inflammatory activation of extracellular signal-regulated kinase and the transcription factor nuclear factor-kB, and the associated neuroinflammation and insulin resistance, but not ERK and NFkB homeostatic functions (such as insulin signaling and neuron growth and survival). Both neuroinflammation and insulin resistance are drivers of Alzheimer’s disease (AD) and Parkinson’s disease (PD). Persistent systematic inflammation and neuroinflammation are key features in patients with neurological symptoms of long COVID. In liver disease, the Company's orphan drug candidate BIV201, is being evaluated for Phase III clinical testing for the reduction of further decompensation in participants with liver cirrhosis and ascites.

What is the price predicton of BIVI Stock?

Wall Street analysts forecast BIVI stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for BIVI is USD with a low forecast of USD and a high forecast of USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

What is BioVie Inc (BIVI)'s revenue for the last quarter?

BioVie Inc revenue for the last quarter amounts to -5.93M USD, decreased -18.94

What is BioVie Inc (BIVI)'s earnings per share (EPS) for the last quarter?

BioVie Inc. EPS for the last quarter amounts to USD, decreased -100.00

How many employees does BioVie Inc (BIVI). have?

BioVie Inc (BIVI) has 13 emplpoyees as of March 11 2026.

What is BioVie Inc (BIVI) market cap?

Today BIVI has the market capitalization of 10.33M USD.